|Bid||80.70 x 900|
|Ask||81.08 x 800|
|Day's range||80.53 - 81.23|
|52-week range||80.53 - 98.52|
|Beta (5Y monthly)||0.53|
|PE ratio (TTM)||18.64|
|Forward dividend & yield||3.20 (3.96%)|
|Ex-dividend date||04 Mar 2021|
|1y target est||104.00|
Here's why they think Bristol Myers Squibb (NYSE: BMY), Novartis (NYSE: NVS), and Viatris (NASDAQ: VTRS) are too cheap to ignore. Prosper Junior Bakiny (Bristol Myers Squibb): Investors are sometimes wary of undervalued companies.
The European Commission approves Deciphera's (DCPH) Qinlock for the treatment of fourth-line gastrointestinal stromal tumor.
The recent acquisition of Dicerna Pharmaceuticals makes Arrowhead Pharmaceuticals look like the next biotech in line to receive a juicy buyout offer.